Trial · NCT07403604
Effect of Insulin Lowering on Lipogenesis
NCT07403604, Phase 1, Recruiting, Columbia University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Effect of Insulin Lowering on Lipogenesis. Trials, record NCT07403604. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07403604
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Insulin Lowering on Lipogenesis
- NCT number
- NCT07403604
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 25 participants, estimated
- Lead sponsor
- Columbia University
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
- Interventions
- Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
- First posted
- 2026-02-11
- Last updated
- 2026-07-06
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hepatic de novo lipogenesis (absolute values) | Study Days 8 and 16 | Percent incorporation of newly synthesized fatty acids into serum or very low-density lipoprotein (VLDL) triglyceride (TG) (units: %) |
| Primary | Hepatic de novo lipogenesis (relative/change) | Study Days 8 and 16 | Percent incorporation of newly synthesized fatty acids into serum or VLDL TG (units: fold difference and/or ∆%) |
| Secondary | Fasting plasma/serum insulin (absolute values) | Study Days 8 and 16 | Measurement of fasting endogenous insulin levels during treatment with diazoxide 2 mpk vs. placebo (units: micro-international units \[µIU\] per mL). |
| Secondary | Fasting plasma/serum insulin (relative/change) | Study Days 8 and 16 | Measurement of fasting endogenous insulin levels during treatment with diazoxide 2 mpk vs. placebo (units: fold difference and/or change in µIU/mL). |
| Secondary | Fasting plasma glucose | Study Days 8 and 16 | Measurement of fasting plasma glucose levels during treatment with diazoxide 2 mpk vs. placebo (units: mg/dL). |
| Secondary | Fasting serum or plasma triglycerides | Study Days 8 and 16 | Measurement of fasting plasma or serum triglyceride levels during treatment with diazoxide 2 mpk vs. placebo (units: mg/dL). |
| Secondary | Fasting plasma free fatty acids | Study Days 8 and 16 | Measurement of fasting plasma free fatty acid levels during treatment with diazoxide 2 mpk vs. placebo (units: mmol/L). |
| Secondary | Steady state plasma glucose (SSPG) during IST | At time points of 150, 160, 170, and 180 minutes during each 3-hour IST protocol | Measurement of plasma glucose at 10-minute intervals during 30-minute steady-state period at the end of each IST (units: mg/dL) |
| Other | Skin de novo lipogenesis | 3 hours | Percent incorporation of newly synthesized fatty acids into sebum from healthy skin and, if present, skin from inflammatory skin lesions (units: %) |
| Other | Deuterium tracer enrichment in body water (measured in blood) | Study Days 8 and 16 | Enrichment of total body water with deuterated water (2H2O/D2O) (units: %) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23DK140614 | Human Models of Selective Insulin Resistance | COOK, JOSHUA ROBERT | COLUMBIA UNIVERSITY HEALTH SCIENCES | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07403604
GET https://conductscience.org/api/trials/v1/NCT07403604/registered